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A B S T R A C T   
Background: Inflammation plays a role in pancreatic cancer. Many medications cause pancreatic inflammation, 
with some leading to a diagnosis of drug-induced pancreatitis (DIP), but few studies have examined these 
medications and pancreatic cancer risk. We therefore investigated the associations between pancreatic cancer 
risk and commonly-prescribed medicines for which there is strongest evidence of DIP. 
Methods: A nested case-control study was undertaken using the Primary Care Clinical Informatics Unit Research 
database containing general practice (GP) records from Scotland. Pancreatic cancer cases, diagnosed between 
1999 and 2011, were identified and matched with up to five controls (based on age, gender, GP practice and date 
of registration). Medicines in the highest category of evidence for DIP, based on a recent systematic review, and 
used by more than 2 % of controls were identified. Odds ratios (OR) and 95 % confidence intervals (CI) for 
associations with pancreatic cancer were calculated using conditional logistic regression after adjusting for 
comorbidities. 
Results: There were 1,069 cases and 4,729 controls. Thirteen medicines in the highest category of evidence for 
DIP were investigated. There was little evidence of an association between any of these medications and 
pancreatic cancer risk apart from metronidazole (adjusted OR 1.69, 95 % CI 1.18, 2.41) and ranitidine (adjusted 
OR 1.37, 95 %CI 1.10, 1.70). However, no definitive exposure-response relationships between these medicines 
and cancer risk were observed. 
Conclusions: There is little evidence that commonly-prescribed medicines associated with inflammation of the 
pancreas are also associated with pancreatic cancer. These findings should provide reassurance to patients and 
prescribing clinicians.   
1. Introduction 
Pancreatic cancer is an aggressive form of cancer. Despite accounting 
for less than 3% (460,000) of new cases globally in 2018, pancreatic 
cancer was the seventh-leading cause of deaths from cancer (432,000) 
[1]. Incidence and mortality is particularly high in Europe, with over 95, 
000 deaths annually and a median survival of 4.6 months [2]. Pancreatic 
cancer is often diagnosed late stage and over the last forty years patient 
outcomes have not markedly improved [3] highlighting the importance 
of primary prevention. 
It is widely accepted that inflammation is involved in the 
development of many cancers [4,5] due to the potential for cell mutation 
and proliferation as the body responds to tissue damage [6]. In partic-
ular, there is evidence of the role of inflammation in pancreatic cancer 
[7]. Chronic pancreatitis is a well-recognised risk factor for pancreatic 
cancer [8] due to interactions of pancreatic stellate cells with pancreatic 
cancer cells, acinar cells and inflammatory cells [9], and several studies 
have reported that acute pancreatitis is also associated with an increased 
risk of pancreatic cancer [10–12]. 
While gallstones [13] and alcohol consumption [14] are considered 
the most common precipitating factors for inflammation of the pancreas, 
there is increased awareness that medications can cause also 
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inflammation which, although rare, can lead to the development of 
acute drug-induced pancreatitis (DIP) [15]. Due to an overreliance on 
clinician case reports and a lack of detailed information derived from 
large-scale population-based studies, DIP is considered a medical con-
dition which can be both overdiagnosed and underdiagnosed [16]. At-
tempts have been made to systematically classify medications into those 
which have the strongest evidence of DIP and are most likely to cause 
inflammation of the pancreas. The number of medications identified as 
possible causes of DIP has increased from 60 in 2007 [15] to 214 in 2020 
[17], and includes a wide variety of drugs such as diuretics [18], es-
trogens [19] and Angiotensin Converting Enzyme (ACE) inhibitors [20]. 
However, studies have not systematically investigated the association 
between these medications and pancreatic cancer risk. We therefore 
investigated the associations between pancreatic cancer and 
commonly-prescribed medicines associated with drug-induced pancre-
atitis using a nested case-control study. 
2. Materials and methods 
2.1. Data source 
Data for this study was obtained from Primary Care Clinical Infor-
mation Unit Research (PCCIUR) [21], a high quality population-based 
database of over two million patients registered at 393 general prac-
tices from across Scotland between 1993 and 2011. PCCIUR data con-
tains up to 20 years of demographic, clinical and diagnostic information 
and has been widely used in epidemiological research [22–25]. 
2.2. Study design 
A historical nested case-control study was conducted using PCCIUR 
data, with data collected prospectively. Cases were patients with a new 
diagnosis of primary pancreatic cancer (Read code B17) between 1999 
and 2011. Cases were excluded if they had a previous cancer, excluding 
non-melanoma skin cancer, or they were diagnosed with other primary 
cancers on the date of diagnosis due to uncertainty about the primary 
cancer and the potential for coding errors. All available controls (alive, 
registered with their GP and free from cancer (with the exception of non- 
melanoma skin cancer)) were identified for each case matching on 
practice, year of birth (plus or minus five years), gender and year of 
registration (in categories). Up to five controls for each case were 
randomly selected from those available, without replacement. The index 
date within each matched set was defined as the diagnosis date of 
pancreatic cancer in the case. Both cases and controls were required to 
have at least three years of follow-up data and remain registered with 
the same general practice over the follow-up period. Cases could be 
sampled as controls prior to diagnosis. 
Within each matched set, the exposure period, i.e. the period of time 
over which medicine use was determined, started on either 1 January 
1993 (as prescriptions before this time were less likely to be electroni-
cally recorded), or the most recent GP registration date if this occurred 
after January 1993. This ensured that all members within each matched 
set had the same exposure period. The exposure period ended one year 
before the index date, to reduce the risk of reverse causality and exclude 
medications that are unlikely to have had sufficient time to cause the 
cancer [26]. 
2.3. Classification and definition of medicine 
The most recent and comprehensive systematic review of medicines 
associated with DIP [17] was used to identify medicines for study in 
relation to pancreatic cancer risk. This review classified evidence for the 
association between 240 medicines and DIP into one of six classes; from 
Class Ia (strongest evidence of an association), Class Ib, Class Ic, Class II, 
Class III, to Class IV (weakest evidence of an association). Medicines 
were assigned to Class Ia if there was at least one case report in humans 
with positive rechallenge (i.e. pancreatitis returned after stopping and 
restarting the drug) and all other causes such as alcohol, hyper-
triglyceridemia/hyperlipidemia, gallstones, and other medicines were 
ruled out. Systemic formulations of Class Ia medicines (single-agent 
drugs and the appropriate constituent parts of combination drugs) were 
extracted from the electronic GP prescribing records within PCCIUR. 
Analyses were restricted to Class Ia medicines that were issued to at least 
2 percent of the controls. 
2.4. Covariates 
The following comorbidities, based upon published Read codes for 
the Charlson Comorbidity Index (CCI) [27], were identified prior to or 
during the exposure period: diabetes, myocardial infarction, coronary 
heart disease, heart failure, peripheral vascular disease, dementia, ce-
rebrovascular disease, chronic obstructive pulmonary disease, osteopo-
rosis, rheumatological disease, renal disease, liver disease, irritable 
bowel disease, human immunodeficiency viruses (HIV) and hemi-
plegia/paraplegia. Additional comorbidities, relevant to pancreatic 
cancer (peptic ulcer, Helicobacter pylori, Hepatitis B & C, gallstones, 
metabolic syndrome), were also identified. Smoking status (non-smoker, 
current smoker, former smoker) and alcohol consumption (non-drinker, 
light or moderate drinker, heavy drinker) were determined from the 
most recent smoking or alcohol record prior to or during the exposure 
period. 
2.5. Statistical analysis 
Descriptive statistics were used to summarise the cases and controls. 
Conditional logistic regression was used to calculate odds ratios (OR) 
and 95 % confidence intervals (CI) for the associations between each 
medicine and pancreatic cancer, with and without adjustment for 
comorbidities. The matched design accounted for age (+/- five years), 
GP practice, gender and year of registration. All analyses adjusted for 
age in years, allowing for the fact that patients were matched in age 
bands rather by calendar year. Exposure-response analyses were con-
ducted calculating ORs for low and high use compared with none, with 
low/high use based upon numbers of prescriptions equal to or below/ 
above the median (among the control patients who were users), 
respectively. 
2.6. Sensitivity analyses 
A number of sensitivity analyses were undertaken as follows: 1) the 
period of time before the index date during which prescriptions were not 
counted was increased from one year to two years to reduce the po-
tential for reverse causation; 2) an exposure of > = 6 items of medicines 
(v less than 6 items) was used as a proxy for higher volume/repeat users; 
3) adjustments were made for comorbidities, smoking and alcohol status 
for the 3,935 patients (67.9 %) with available data; 4) analyses adjusting 
for comorbidities, smoking and alcohol status were repeated using 
multiple imputation with chained equations (MICE) techniques to 
impute smoking and alcohol status. This is a simulation-based method 
appropriate for handling missing data when it is assumed that such 
values are missing at random or missing completely at random. Ordered 
logit models were used with age, gender, deprivation and comorbidities 
for the imputations, stratified by case-control status, and using 25 im-
putations [28]. 
All statistical analyses were undertaken using Stata 15 [29]. Results 
were held to be significant if they referred to statistical significance on a 
two-sided design-based test evaluated at the 0.05 % level. 
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3. Results 
3.1. Descriptive statistics 
1,069 cases and 4,729 controls were identified in the data. 914 cases 
(85.6 %) had at least 4 matched controls. The median exposure period 
was 8.9 years (Interquartile range (IQR) (6.0, 11.7)). The median age of 
all patients at diagnosis was 69 years (IQR 59–77) and 52.0 % (3,014) 
were female. The most commonly diagnosed comorbidities were coro-
nary heart disease (952 (16.42 %)), diabetes (574 (9.9 %)) and chronic 
obstructive pulmonary disease (COPD) (449 (7.7 %). 389 (6.7 %) pa-
tients were diagnosed with gallstones. 35 out of a possible 45 Class Ia 
medicines were identified within PCCIUR, of which 13 were prescribed 
to at least 2% of the controls during the exposure period. Characteristics 
of the cases and controls are summarised in Table 1. 
3.2. Associations between medicines and pancreatic cancer 
Results from the main analyses are illustrated in Fig. 1 and reported 
in Table 2. Overall, the majority of Class Ia medicines were not associ-
ated with an increased risk of pancreatic cancer after adjustment for 
comorbid conditions. Only two medicines were significantly associated 
with an increased risk of pancreatic cancer (metronidazole: adjusted 
odds ratio (ORadj) 1.69, 95 % CI (1.18, 2.41), p = 0.004; ranitidine: 
ORadj 1.37, 95 %CI (1.10,1.70), p = 0.005). However, neither exhibited 
strong evidence of an exposure-response relationship with cancer risk. 
For ranitidine, the adjusted odds ratio comparing six or more pre-
scriptions with none was 1.24 (95 % CI 0.91, 1.69; p = 0.179), whereas 
the adjusted odds ratio comparing five or fewer prescriptions with none 
was 1.49 (95 %CI 1.12.1.99; p = 0.007). For metronidazole, the adjusted 
odds ratio comparing two or more prescriptions with none was 1.71 (95 
%CI 0.66, 4.43; p = 0.272), whereas the adjusted odds ratio comparing 
one prescription with none was 1.69 (95 %CI 1.16, 2.45; p = 0.006). 
Although there was little association with any use or erythromycin and 
pancreatic cancer (ORadj 1.15, 95 %CI (0.91, 1.45), p = 0.238), there 
was evidence that patients issued two or more erythromycin pre-
scriptions were associated with higher pancreatic cancer risk (ORadj 
1.40, 95 %CI (1.00, 1.97), p = 0.049). 
The results from the sensitivity analyses are listed in Table 3. 
Increasing the lag-time from one year to two years or adjusting for 
smoking and alcohol use had no substantive impact on the reported 
associations between prescribed medicines and risk of pancreatic can-
cer. It was not possible to estimate an odds ratio for the association 
between six or more items of metronidazole and pancreatic cancer as all 
Table 1 
Characteristics of cases and controls.  
Variable Category Cases 
n (%) 
Controls 
n (%)   
n = 1,069 n = 4,729 
Length of exposure period (years): median (IQR)  8.9 (6.0,11.7) 8.9 (6.0,11.7) 
Year of diagnosis/index date: median (IQR)  2006 (2003,2007) 2006 (2003, 2007) 
Age at diagnosis/index date (years) 0− 39 11 (1.1 %) 71 (1.5 %)  
40− 59 198 (18.5 %) 1,179 (24.9 %)  
60− 79 636 (59.5 %) 2,663 (56.3 %)  
80 + 224 (21.0 %) 816 (17.3 %) 
Deprivation quintile 1 (least deprived) 67 (6.3 %) 287 (6.1 %)  
2 210 (19.6 %) 940 (19.9 %)  
3 84 (7.9 %) 370 (7.8 %)  
4 271 (25.4 %) 1,189 (25.1 %)  
5 (most deprived) 275 (25.7 %) 1,227 (25.95 %) 
Gender male 516 (48.3 %) 2,268 (48.0 %)  
female 553 (51.7 %) 2,461 (52.0 %) 
Smoking statusa never smoked 338 (31.6 %) 1,800 (38.1 %)  
ex-smoker 278 (26.0 %) 1,115 (23.6 %)  
current smoker 287 (26.9 %) 867 (18.3 %)  
missing 166 (15.5 %) 947 (20.0 %) 
Alcohol consumptiona non-drinker 179 (16.7 %) 747 (15.8 %)  
light/moderate 555 (51.9 %) 2,363 (50.0 %)  
heavy drinker 35 (3.3 %) 161 (3.4 %)  
missing 300 (28.1 %) 1,458 (30.8 %)  
Comorbidities diagnosed prior to or during the exposure period 
Diabetes  178 (16.7 %) 396 (8.4 %) 
Myocardial infarction  89 (8.3 %) 299 (6.3 %) 
Coronary heart disease  212 (19.8 %) 740 (15.7 %) 
Heart failure  49 (4.6 %) 143 (3.0 %) 
Peripheral vascular disease  53 (5.0 %) 205 (4.3 %) 
Dementia  9 (0.8 %) 70 (1.5 %) 
Cerebrovascular disease  83 (7.8 %) 323 (6.8 %) 
Chronic obstructive pulmonary disease  115 (10.8 %) 334 (7.1 %) 
Osteoporosis  44 (4.1 %) 164 (6.5 %) 
Rheumatological disease  44 (4.1 %) 121 (2.6 %) 
Renal disease  48 (4.5 %) 221 (4.7 %) 
Liver disease  17 (1.6 %) 26 (0.6 %) 
Irritable bowel disease  58 (5.4 %) 287 (6.1 %) 
Human immunodeficiency viruses  <5 (<0.5 %) <5 (<0.1 %) 
Hemiplegia/paraplegia  <5 (<0.5 %) 23 (0.5 %) 
Peptic ulcer  95 (8.9 %) 354 (7.5 %) 
Helicobacter pylori  <5 (<0.5 %) <5 (<0.1 %) 
Hepatitis B/C  <5 (<0.5 %) <5 (<0.1 %) 
Gallstones  89 (8.3 %) 300 (6.3 %) 
Metabolic syndrome  <5 (<0.5 %) <5 (<0.1 %) 
Abbreviations: IQR: inter-quartile range; DIP: drug induced pancreatitis. 
a Most recent record in patient’s clinical history prior to one-year lag. 
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cases were issued with less than six metronidazole prescriptions during 
the exposure period. 
4. Discussion 
4.1. Principal findings 
In this study we used a population-based clinical database to 
examine associations between commonly-prescribed medicines associ-
ated with inflammation of the pancreas and pancreatic cancer. Of the 13 
medicines studied, two (metronidazole, ranitidine) were significantly 
associated with an increased risk of pancreatic cancer. However, there 
was little evidence of an exposure-response relationship with pancreatic 
cancer for these medicines. There was some evidence of an increased 
risk with pancreatic cancer for patients who received a greater number 
of prescriptions for erythromycin. The remaining medicines were not 
associated with an altered risk of pancreatic cancer after adjusting for 
comorbidities. 
4.2. Context of other studies 
To our knowledge this is the first study which has examined asso-
ciations between a wide range of medications which have been shown to 
cause inflammation of the pancreas including acute pancreatitis and 
pancreatic cancer risk. Previous studies of medicine/pancreatic cancer 
associations have tended to study individual medicines [30] or medi-
cines from the same family [31]. 
The medicines we studied were identified from a systematic review 
of the evidence of their impact on drug-induced pancreatitis and have 
previously been classed as having the strongest evidence of causing DIP. 
In our analyses use of ranitidine, a histamine type-2 receptor agonist 
(H2RA), was associated with a significantly increased risk of pancreatic 
cancer although no exposure-response relationship was observed. Con-
cerns about the identification of low levels in ranitidine of N-nitro-
sodimethylamine (NDMA), a probable human carcinogen, led the Food 
and Drug Administration (FDA) in the United States in 2019 to withdraw 
all products which include ranitidine [32]. However a recent study of 
over 65 million American adults reported that users of ranitidine have a 
lower risk of pancreatic cancer than users of famotidine (ORadj 0.63, 95 
%CI (0.61, 0.65)), another H2RA commonly prescribed for the treatment 
of excess stomach acid [33]. In supplementary analyses of PCCIUR data 
neither famotidine (ORad 2.71, 95 %CI (0.41, 17.81), p = 0.300) nor 
nizatidine (ORad 1.01, 95 %CI (0.40,2.54), p = 0.979 were significantly 
associated with cancer risk. Findings from these two studies may vary 
for a variety of reasons such as sampling variation, differences in the 
study populations (e.g. age distributions), relatively lower levels of 
Fig. 1. Associations of commonly-prescribed Class Ia medicines with pancreatic cancer .  
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Table 2 
Associations of commonly-prescribed Class Ia medicines with pancreatic cancer.  
Medicine Category No (%) cases No (%) controls Unadjusted OR (95 %CI) Comorbiditya adjusted OR (95%CI) 
cimetidine 
Never 995 (93.1 %) 4,448 (94.1 %) 1.00 1.00 
Any 74 (6.9 %) 281 (5.9 %) 1.13 (0.85,1.50) 1.09 (0.81,1.46) 
Lower usage (1− 3) 35 (3.3 %) 144 (3.0 %) 1.06 (0.72,1.57) 1.08 (0.72,1.61) 
Higher usage (> = 4) 39 (3.7 %) 137 (2.9 %) 1.20 (0.82,1.76) 1.10 (0.74,1.63)  
codeine 
Never 738 (69.0 %) 3,343 (70.7 %) 1.00 1.00 
Any 331 (31.0 %) 1,386 (29.3 %) 1.06 (0.90,1.24) 1.00 (0.84,1.18) 
Lower usage (1− 3) 176 (16.5 %) 750 (15.9 %) 1.05 (0.87,1.28) 1.00 (0.82,1.22) 
Higher usage (> = 4) 155 (14.5 %) 636 (13.4 %) 1.07 (0.86,1.32) 0.99 (0.79,1.24)  
conjugated estrogensb 
Never 522 (94.4 %) 2,269 (92.2 %) 1.00 1.00 
Any 31 (5.6 %) 192 (7.8 %) 0.83 (0.54,1.26) 0.86 (0.56,1.32) 
Lower usage (1− 6) 16 (2.9 %) 102 (4.1 %) 0.80 (0.45,1.40) 0.81 (0.46,1.44) 
Higher usage (> = 7) 15 (2.7 %) 90 (3.7 %) 0.86 (0.48,1.56) 0.93 (0.51,1.70)  
erythromycin 
Never 943 (88.2 %) 4,247 (89.8 %) 1.00 1.00 
Any 126 (11.8 %) 482 (10.2 %) 1.27 (1.02,1.59) 1.15 (0.91,1.45) 
Lower usage (1− 1) 67 (6.3 %) 318 (6.7 %) 1.06 (0.80,1.41) 1.01 (0.75,1.35) 
Higher usage (> = 2) 59 (5.5 %) 164 (3.5 %) 1.67 (1.21,2.32) 1.40 (1.00,1.97)  
furosemide 
Never 924 (86.4 %) 4,137 (87.5 %) 1.00 1.00 
Any 145 (13.6 %) 592 (12.5 %) 0.96 (0.78,1.19) 0.75 (0.60,0.95) 
Lower usage (1− 13) 65 (6.1 %) 303 (6.4 %) 0.88 (0.66,1.17) 0.70 (0.52,0.95) 
Higher usage (> = 14) 80 (7.5 %) 289 (6.1 %) 1.05 (0.80,1.38) 0.82 (0.60,1.11)  
lisinopril 
Never 978 (91.5 %) 4,390 (92.8 %) 1.00 1.00 
Any 91 (8.5 %) 339 (7.2 %) 1.12 (0.87,1.46) 1.00 (0.77,1.31) 
Lower usage (1− 12) 40 (3.7 %) 175 (3.7 %) 0.93 (0.65,1.34) 0.86 (0.59,1.25) 
Higher usage (> = 13) 51 (4.8 %) 164 (3.5 %) 1.35 (0.96,1.90) 1.17 (0.82,1.66)  
metformin 
Never 984 (92.0 %) 4,521 (95.6 %) 1.00 1.00 
Any 85 (8.0 %) 208 (4.4 %) 1.93 (1.47,2.53) 0.79 (0.55,1.14) 
Lower usage (1− 23) 58 (5.4 %) 108 (2.3 %) 2.47 (1.76,3.45) 0.99 (0.65,1.50) 
Higher usage (> = 24) 27 (2.5 %) 100 (2.1 %) 1.32 (0.85,2.05) 0.56 (0.33,0.93)  
metronidazole 
Never 1,017 (95.1 %) 4,586 (97.0 %) 1.00 1.00 
Any 52 (4.9 %) 143 (3.0 %) 1.73 (1.23,2.43) 1.69 (1.18,2.41) 
Lower usage (1− 1) 46 (4.3 %) 121 (2.6 %) 1.75 (1.22,2.50) 1.69 (1.16,2.45) 
Higher usage (> = 2) 6 (0.6 %) 22 (0.5 %) 1.59 (0.63,4.03) 1.71 (0.66,4.43)  
paracetamol 
Never 523 (48.9 %) 2,566 (54.3 %) 1.00 1.00 
Any 546 (51.1 %) 2,163 (45.7 %) 1.19 (1.02,1.38) 1.09 (0.93,1.27) 
Lower usage (1− 6) 253 (23.7 %) 1,118 (23.6 %) 1.08 (0.91,1.29) 1.01 (0.84,1.21) 
Higher usage (> = 7) 293 (27.4 %) 1,045 (22.1 %) 1.32 (1.10,1.59) 1.19 (0.98,1.44)  
pravastatin 
Never 1,024 (95.8 %) 4,594 (97.2 %) 1.00 1.00 
Any 45 (4.2 %) 135 (2.9 %) 1.54 (1.07,2.22) 1.33 (0.90,1.95) 
Lower usage (1− 14) 22 (2.1 %) 69 (1.5 %) 1.42 (0.87,2.33) 1.22 (0.73,2.04) 
Higher usage (> = 15) 23 (2.1 %) 66 (1.4 %) 1.68 (1.01,2.81) 1.46 (0.85,2.50)  
ramipril 
Never 1,003 (93.8 %) 4,453 (94.2 %) 1.00 1.00 
Any 66 (6.2 %) 276 (5.8 %) 0.98 (0.73,1.31) 0.74 (0.54,1.01) 
Lower usage (1− 12) 32 (3.0 %) 141 (3.0 %) 0.94 (0.63,1.40) 0.74 (0.49,1.12) 
Higher usage (> = 13) 34 (3.2 %) 135 (2.9 %) 1.03 (0.69,1.52) 0.74 (0.49,1.13)  
ranitidine 
Never 926 (86.6 %) 4,287 (90.7 %) 1.00 1.00 
Any 143 (13.4 %) 442 (9.3 %) 1.45 (1.17,1.79) 1.37 (1.10,1.70) 
Lower usage (1− 5) 79 (7.4 %) 230 (4.9 %) 1.61 (1.22,2.12) 1.49 (1.12,1.99) 
Higher usage (> = 6) 64 (6.0 %) 212 (4.5 %) 1.28 (0.95,1.73) 1.24 (0.91,1.69)  
simvastatin 
Never 862 (80.6 %) 3,975 (84.1 %) 1.00 1.00 
Any 207 (19.4 %) 754 (15.9 %) 1.23 (1.02,1.48) 0.99 (0.80,1.22) 
Lower usage (1− 14) 117 (10.9 %) 381 (8.1 %) 1.38 (1.09,1.74) 1.12 (0.87,1.44) 
Higher usage (> = 15) 90 (8.4 %) 373 (7.9 %) 1.07 (0.83,1.39) 0.84 (0.63,1.12) 
Abbreviations: OR: odds ratio; CI: confidence interval. 
a Comorbidities include diabetes, myocardial infarction, coronary heart disease, heart failure, peripheral vascular disease, dementia, cerebrovascular disease, 
chronic obstructive pulmonary disease, osteoporosis, rheumatological disease, renal disease, liver disease, irritable bowel disease, human immunodeficiency viruses, 
hemiplegia/paraplegia, peptic ulcer, helicobacter pylori, Hepatitis B/C, gallstones, metabolic syndrome. 
b Females only. 
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Table 3 
Sensitivity analyses for associations of commonly-prescribed Class Ia medicines and pancreatic cancer.  
Medicine Analysis Exposure No (%) cases No (%) controls Unadjusted OR (95 %CI) Comorbidity a adjusted OR (95%CI) 
cimetidine 
2 year lag Any 70(6.6 %) 267(5.7 %) 1.12(0.84,1.49) 1.07(0.79,1.45) 
Lifestyle complete b Any 51(6.7 %) 215(6.8 %) 0.96(0.67,1.37) 0.91(0.63,1.32) 
Lifestyle MI b Any 74(6.9 %) 281(5.9 %) 1.13(0.85,1.50) 1.07(0.80,1.43) 
1 year lag > = 6 items 31(2.9 %) 119(2.5 %) 1.07(0.71,1.63) 0.98(0.64,1.51)  
codeine 
2 year lag Any 278(26.0 %) 1,189(25.1 %) 1.02(0.86,1.21) 0.96(0.80,1.14) 
Lifestyle complete b Any 269(35.4 %) 1,097(34.5 %) 1.06(0.87,1.29) 0.98(0.80,1.21) 
Lifestyle MI b Any 331(31.0 %) 1,386(29.3 %) 1.06(0.90,1.24) 0.99(0.84,1.17) 
1 year lag > = 6 items 128(12.0 %) 517(10.9 %) 1.07(0.85,1.33) 1.00(0.79,1.26)  
conjugated estrogens c 
2 year lag Any 30(5.4 %) 187(7.6 %) 0.83(0.54,1.27) 0.86(0.56,1.32) 
Lifestyle complete b Any 26(6.6 %) 161(9.5 %) 0.79(0.49,1.28) 0.80(0.49,1.31) 
Lifestyle MI b Any 31(5.6 %) 192(7.8 %) 0.83(0.54,1.26) 0.83(0.54,1.27) 
1 year lag > = 6 items 15(2.7 %) 100(4.1 %) 0.76(0.42,1.38) 0.78(0.43,1.43)  
erythromycin 
2 year lag Any 115(10.8 %) 432(9.1 %) 1.28(1.02,1.61) 1.16(0.91,1.47) 
Lifestyle complete b Any 105(13.8 %) 381(12.0 %) 1.28(0.99,1.66) 1.13(0.86,1.48) 
Lifestyle MI b Any 126(11.8 %) 482(10.2 %) 1.27(1.02,1.59) 1.17(0.93,1.48) 
1 year lag > = 6 items 7(0.7 %) 18(0.4 %) 1.71(0.70,4.21) 1.63(0.65,4.11)  
furosemide 
2 year lag Any 125(11.7 %) 529(11.2 %) 0.91(0.73,1.14) 0.71(0.56,0.91) 
Lifestyle complete b Any 117(15.4 %) 432(13.6 %) 0.97(0.75,1.26) 0.74(0.55,0.99) 
Lifestyle MI b Any 145(13.6 %) 592(12.5 %) 0.96(0.78,1.19) 0.76(0.60,0.96) 
1 year lag > = 6 items 96(9.0 %) 406(8.6 %) 0.89(0.69,1.14) 0.70(0.53,0.92)  
lisinopril 
2 year lag Any 71(6.6 %) 280(5.9 %) 1.07(0.80,1.43) 0.93(0.69,1.26) 
Lifestyle complete b Any 82(10.8 %) 274(8.6 %) 1.20(0.89,1.61) 1.08(0.79,1.48) 
Lifestyle MI b Any 91(8.5 %) 339(7.2 %) 1.12(0.87,1.46) 1.03(0.79,1.36) 
1 year lag > = 6 items 64(6.0 %) 233(4.9 %) 1.14(0.85,1.55) 1.02(0.75,1.39)  
metformin 
2 year lag Any 70(6.6 %) 180(3.8 %) 1.86(1.38,2.49) 0.78(0.53,1.13) 
Lifestyle complete b Any 75(9.9 %) 184(5.8 %) 1.92(1.40,2.62) 0.76(0.50,1.17) 
Lifestyle MI b Any 85(8.0 %) 208(4.4 %) 1.93(1.47,2.53) 0.83(0.58,1.21) 
1 year lag > = 6 items 68(6.4 %) 167(3.5 %) 1.93(1.44,2.61) 0.84(0.58,1.23)  
metronidazole 
2 year lag Any 43(4.0 %) 121(2.6 %) 1.69(1.17,2.46) 1.69(1.15,2.49) 
Lifestyle complete b Any 43(5.7 %) 114(3.6 %) 1.93(1.29,2.87) 1.91(1.25,2.91) 
Lifestyle MI b Any 52(4.9 %) 143(3.0 %) 1.73(1.23,2.43) 1.68(1.18,2.41) 
1 year lag > = 6 items 0(0.0 %) 1(0.0 %) – –  
paracetamol 
2 year lag Any 496(46.4 %) 1,964(41.5 %) 1.16(1.00,1.35) 1.07(0.92,1.25) 
Lifestyle complete b Any 424(55.8 %) 1,624(51.1 %) 1.20(0.99,1.45) 1.08(0.88,1.32) 
Lifestyle MI b Any 546(51.1 %) 2,163(45.7 %) 1.19(1.02,1.38) 1.07(0.91,1.25) 
1 year lag > = 6 items 308(28.8 %) 1,102(23.3 %) 1.28(1.09,1.51) 1.19(1.00,1.41)  
pravastatin 
2 year lag Any 43(4.0 %) 123(2.6 %) 1.63(1.12,2.38) 1.42(0.96,2.11) 
Lifestyle complete b Any 40(5.3 %) 119(3.8 %) 1.40(0.93,2.10) 1.28(0.82,1.98) 
Lifestyle MI b Any 45(4.2 %) 135(2.9 %) 1.54(1.07,2.22) 1.33(0.90,1.96) 
1 year lag > = 6 items 33(3.1 %) 102(2.2 %) 1.47(0.96,2.23) 1.28(0.82,1.99)  
ramipril 
2 year lag Any 48(4.5 %) 223(4.7 %) 0.88(0.63,1.23) 0.63(0.44,0.90) 
Lifestyle complete b Any 60(7.9 %) 237(7.5 %) 0.95(0.69,1.31) 0.72(0.50,1.02) 
Lifestyle MI b Any 66(6.2 %) 276(5.8 %) 0.98(0.73,1.31) 0.74(0.54,1.01) 
1 year lag > = 6 items 45(4.2 %) 193(4.1 %) 0.96(0.68,1.36) 0.70(0.49,1.01)  
ranitidine 
2 year lag Any 129(12.1 %) 412(8.7 %) 1.39(1.12,1.74) 1.32(1.05,1.66) 
Lifestyle complete b Any 115(15.1 %) 320(10.1 %) 1.48(1.14,1.93) 1.37(1.05,1.81) 
Lifestyle MI b Any 143(13.4 %) 442(9.3 %) 1.45(1.17,1.79) 1.35(1.08,1.68) 
1 year lag > = 6 items 64(6.0 %) 212(4.5 %) 1.24(0.92,1.68) 1.20(0.88,1.63)  
simvastatin 
2 year lag Any 165(15.4 %) 625(13.2 %) 1.16(0.95,1.42) 0.91(0.73,1.15) 
Lifestyle complete b Any 184(24.2 %) 650(20.5 %) 1.12(0.90,1.39) 0.93(0.73,1.19) 
Lifestyle MI b Any 207(19.4 %) 754(15.9 %) 1.23(1.02,1.48) 0.99(0.80,1.22) 
1 year lag > = 6 items 152(14.2 %) 567(12.0 %) 1.16(0.94,1.43) 0.93(0.74,1.18) 
Abbreviations: OR: odds ratio; CI: confidence interval; MI: multiple imputation. 
a Comorbidities include diabetes, myocardial infarction, coronary heart disease, heart failure, peripheral vascular disease, dementia, cerebrovascular disease, 
chronic obstructive pulmonary disease, osteoporosis, rheumatological disease, renal disease, liver disease, irritable bowel disease, human immunodeficiency viruses, 
hemiplegia/paraplegia, peptic ulcer, helicobacter pylori, Hepatitis B & C, gallstones, metabolic syndrome. 
b Additionally adjusted for smoking and alcohol status. 
c Females only. 
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prescribing of famotidine in Scotland, and different adjustments for 
confounding variables. As such the association between ranitidine and 
pancreatic cancer is yet to be determined. 
No significant association was observed in our study between 
cimetidine, another H2RA, and pancreatic cancer. Although a Danish 
study of patients prescribed cimetidine as a treatment for gastric ulcer 
observed an increased risk of pancreatic cancer in the first year of 
follow-up, they concluded this was unlikely to be due to any carcino-
genic action of the drug [34]. More recently cimetidine has been shown 
to exhibit anti-tumour action via a number of mechanisms, such as 
reducing cancer cell proliferation, immunomodulation, cell adhesion 
and angiogenesis [35]. 
We observed that metronidazole, a nitroimidazole antibiotic, was 
associated with a higher risk of pancreatic cancer, as were patients with 
a greater number of erythromycin (a mitochondrially-targeted anti-
biotic) prescriptions. We cannot infer much about any potential causal 
relationship between either antibiotic and pancreatic cancer use to low 
numbers of patients using two or more prescriptions making an 
exposure-response relationship impossible to investigate. These results 
may reflect residual confounding; metronidazole is prescribed to reduce 
infection, such as reducing the risk of developing infected pancreatic 
necrosis in patients with necrotizing pancreatitis (i.e. where part of the 
pancreas dies) [36]. 
Metformin is the Class Ia medicine most commonly studied in rela-
tion to pancreatic cancer risk. However, results from pharmacoepide-
miologic studies are varied. A nested case-control study of 529 
pancreatic cancer cases and 5,000 controls from The Health Improve-
ment Network (THIN) reported that metformin was associated with 
increased pancreatic cancer risk [37]. Bodmer et al. reported that use of 
metformin was associated with a decreased risk of pancreatic cancer in 
women only [30], whereas Walker et al. reported that there was no 
association between metformin and pancreatic cancer among patients 
with type 2 diabetes [38]. The potential of metformin, an antidiabetic 
drug, to have cancer risk-preventing properties has been known for 
many years [39]. Although metformin use was associated with a 
decreased risk of pancreatic cancer in our study, after adjusting for 
comorbidities, including diabetes, this association was not of statistical 
significance. 
The remainder of our results are generally consistent with the liter-
ature; an increased risk of pancreatic cancer was not observed with use 
of hormone replacement therapy (HRT) medicines [40,41], paracetamol 
[31] or statins [42,43]. 
4.3. Strengths and limitations of study 
There are a number of strengths to our study. The PCCIUR is a 
nationally-representative database, covering 15 % of Scottish patients. 
The linking of practice data to Scottish Cancer Registry data means there 
is a high coverage of cancer cases and a relatively long exposure period 
(approximately nine years). We used the most recent systematic review 
of medicines associated with DIP and analysed medicines which are 
commonly prescribed and for which there is the strongest clinical evi-
dence of an association with drug induced pancreatitis, such as the 
elimination of other causes and presentation after re-challenge. Class Ia 
medicines not identified in our sample are either not currently licensed 
or are rarely prescribed within the United Kingdom (UK). We were able 
to adjust for a wide range of confounders. 
However, there are inevitably limitations to this study. We did not 
have access to any secondary care prescribing details, such as hospital 
discharge summaries. However, if a medicine was initiated in secondary 
care for long-term use, we would expect it to be identified in subsequent 
GP prescribing records. Another limitation is our inability to account for 
over-the-counter (OTC) purchases of medicines. Ranitidine, for 
example, was licensed for OTC purchase in the UK January 1995 [44], 
but is only available OTC for short-term use (less than 2 weeks), at low 
doses (75 mg) and for limited indications (short-term symptomatic relief 
of heartburn, dyspepsia and hyperacidity) [45]. A previous methodo-
logical study has shown that healthcare datasets can produce valid es-
timates of medications despite OTC use [46]. 
We do not know the extent to which patients took their medicines, 
although results using an exposure of six or more items, as a proxy for 
longer-term use, were similar to those with an exposure of any medicine. 
We were unable to control for body mass index or other risk factors (such 
as genetic risk factors) as these were not recorded for the majority of 
PCCIUR patients, and some of the associations observed may be due to 
residual confounding. Finally, it is possible that the inclusion of all users 
of a given medicine during the exposure period, rather than new users, 
may result in the misclassification of drug use due to not counting 
medicines prescribed prior to the start of the exposure period [47]. This 
is a necessary component of the study design in order to make a fair 
comparison between cases and their matched controls. A new-user 
design, which only includes patients who begin a course of medicine, 
reduces this risk, but may be of limited value if long-term or historical 
medicine use is thought to alter cancer risk [48]. 
4.4. Implications for policy and research 
Many of the medicines investigated are prescribed long-term for 
common medical conditions. Our study suggests that any inflammation 
of the pancreas which arises from taking these medicines does not 
appear to be associated with an increased risk of pancreatic cancer. 
These findings should provide some reassurance to patients who take 
these medicines for other conditions. However, given the increased risk 
of pancreatic cancer associated with ranitidine in our study, and current 
controversies concerning NDMA, we recommend that further studies of 
the association between ranitidine and pancreatic cancer take place over 
time-frames and/or in countries where ranitidine was only available on 
prescription. 
5. Conclusions 
In our study, medications recently classified as having the strongest 
evidence for causing drug-induced pancreatitis did not appear to be 
associated with pancreatic cancer. These findings should provide reas-
surance to patients regularly taking these medicines and doctors who are 
prescribing them. 
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